Monoclonal antibody specific for human basal cell surface antigen

• US 4,886,745 A
• Filed: 03/30/1984
• Issued: 12/12/1989
• Est. Priority Date: 03/30/1984
• Status: Expired due to Fees

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Original Assignee: Syntec Incorporated (Atos SE)
• Inventors: Morhenn, Vera
• Primary Examiner(s): Nucker, Christine M.
• Application Number:
  US06/595,075
• Time in Patent Office: 2,083 Days
• Field of Search: 935/106, 935/107, 935/108, 935/95, 935/110, 436/548, 436/800, 436/536, 436/808, 436/501, 436/503, 436/813, 435/68, 435/172.2, 435/240, 435/241, 435/948, 435/43, 435/7, 435/240.27, 260/112 R, 424/85, 424/86, 424/87, 424/3, 424/7.1, 128/630, 128/1, 128/1.1, 128/751
• US Class Current: 435/7.23
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: Y10S 435/948 using viruses or cell lines
• CPC Class Codes: Y10S 436/80 Fluorescent dyes, e.g. rhodamine
• CPC Class Codes: Y10S 436/808 Automated or kit
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 530/808 Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
• CPC Class Codes: Y10S 530/809 Fused cells, e.g. hybridoma

Abstract

The present invention is concerned with novel monoclonal antibodies specific for an antigenic site on a protein characteristic of a human basal cell and a malignant squamous cell. The antibodies do not bind to mesenchymal cells such as fibroblasts and endothelial cells. The protein on the cell surface which binds to one of the antibodies has a molecular weight of about 120,000 as determined by one dimensional gel electrophoresis. The antibodies find use in diagnostic methods such as the detection of malignant cells, e.g., the detection of residual tumor cells in skin subjected to microscopically-controlled surgery.

Claims

1. A monoclonal antibody that binds to an antigenic site on a protein characteristic of a human basal cell surface and a human malignant squamous cell and binding fragments of said antibody, wherein said protein is characterized as having a molecular weight of about 120,000 daltons as determined by polyacrylamide gel electrophoresis.

2. The monoclonal antibody of claim 1 obtained from a hybrid continuous cell line having the identifying characteristics of A.T.C.C. HB8530.

3. A hybrid continuous cell line having the identifying characteristic of A.T.C.C. HB8530.

4. A method for determining the presence of a malignant condition in tissue, which comprises

(a) contacting a specimen of tissue suspected of a malignant condition with an antibody that binds to an antigenic site characteristic of a human basal cell, said tissue usually not containing normal basal cells, said antibody being capable of binding to human normal and malignant basal cells and human malignant squamous cells and capable of distinguising such cells from other cell types in said specimen, under conditions for binding of said antibody to said specimen, and

(b) observing the presence of binding of said antibody to said specimen, said binding being related to the presence of a malignant condition in said tissue.

5. The method of claim 4 wherein the antibody is an antibody obtained from a hybrid continuous cell line having the identifying characteristics of A.T.C.C. HB8530 or a binding fragment of said antibody.

6. The method of claim 4 wherein the extent of binding is determined by contacting said specimen with a conjugate of a label and specific binding partner for said monoclonal antibody, said label being capable of producing a detectible signal.

7. The method of claim 4 wherein the monoclonal antibody is conjugated to a label capable of producing a detectible signal.

8. The method of claim 6 wherein the labeled specific binding partner for said monoclonal antibody is an antibody specific for said monoclonal antibody.

9. The method of claim 7 wherein the label is a chromophore.

10. In an in vitro method of microscopically controlled surgery to remove a tumor wherein a clinically visible tumor is removed surgically and the next layer of tissue is excised and checked for residual tumor cells with a light microscope, the improvement wich comprises using a monoclonal antibody that binds to an antigenic site characteristic of a human normal and malignant basal cell surface and a human malignant squamous cell to detect residual tumor cells, the area adjacent said tumor cells usually not containing normal basal cells.